Atopica (cyclosporine capsules USP modified) is an FDA-approved, prescription-only immunosuppressant for the control of atopic dermatitis in dogs weighing at least 4 pounds (1.8 kg) and at least 6 months of age. It is the oldest non-steroidal prescription drug specifically approved for canine atopic dermatitis — on the market for over 20 years — and it remains one of the most prescribed options for dogs whose environmental allergies are not controlled by antihistamines, fatty acids, or topical therapy alone. In clinical trials, approximately 74% of atopic dogs showed good-to-excellent response to cyclosporine, and about 70% achieved at least a 50% reduction in skin lesion scores.

This article covers how cyclosporine works at the cellular level, what the FDA label says about safety and monitoring, when Atopica fits in the allergy treatment ladder, when it does not, and how it compares to newer options like Apoquel (oclacitinib), Cytopoint (lokivetmab), and Zenrelia (ilunocitinib).

Quick answer

Atopica is a daily oral capsule that suppresses the T-cell–driven inflammation underlying atopic dermatitis. The labeled starting dose is 5 mg/kg once daily. After 4 to 8 weeks — once itch and skin lesions improve — most dogs can taper to every-other-day dosing, and some reach twice-weekly dosing. It is not a steroid. It is not a fast-acting drug. It is not a cure. It is a long-term immunomodulatory medication that requires patience during the initial loading phase and ongoing veterinary monitoring.

How cyclosporine works

Cyclosporine binds to a cellular protein called cyclophilin. The cyclosporine–cyclophilin complex then inhibits calcineurin, an enzyme that normally activates a transcription factor called NFAT (nuclear factor of activated T cells). When NFAT cannot be activated, T cells cannot produce interleukin-2 (IL-2), the key cytokine that drives T-cell proliferation.

The downstream effects are broad:

• Reduced activation and proliferation of T-helper cells and cytotoxic T cells
• Decreased production of inflammatory cytokines beyond IL-2 (IL-4, IL-5, IFN-gamma)
• Reduced mast cell activation and eosinophil recruitment
• Decreased histamine release
• Suppressed antigen presentation

This broad suppression of the allergic inflammatory cascade is why cyclosporine is effective in atopic dermatitis — but also why the label classifies it as a systemic immunosuppressant with associated risks.

Why formulation matters

Not all cyclosporine products are interchangeable. Atopica uses a microemulsion (modified) formulation that is ultramicronized for better gastrointestinal absorption in dogs. Older human formulations like Sandimmune (non-microemulsified cyclosporine) have unpredictable absorption and are not recommended for veterinary use. Generic human cyclosporine products may also have different bioavailability in dogs compared to Atopica.

Compounded cyclosporine should be avoided — the Merck Veterinary Manual and veterinary pharmacology literature specifically note that compounding can destroy the microemulsion and result in poor or erratic absorption.

Generic veterinary-approved alternatives include Cyclavance (cyclosporine oral solution) and Modulis (cyclosporine oral solution). These products use the same microemulsion technology and are available in some markets as lower-cost alternatives to Atopica. If your veterinarian recommends a generic, ensure it is a microemulsion (modified) formulation — not a compounded product or a non-microemulsified human generic.

Extra-label uses

While Atopica is FDA-approved only for atopic dermatitis in dogs, cyclosporine is widely used off-label for a range of immune-mediated and inflammatory conditions, including:

• Perianal fistulae (anal furunculosis) — typically at higher doses (7.5 mg/kg/day)
• Immune-mediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (IMT)
• Inflammatory bowel disease (IBD)
• Sebaceous adenitis
• Immune-mediated polyarthritis
• Pemphigus and lupus (SLE)
• Chronic hepatitis
• Certain keratinization disorders

These uses are extra-label and require veterinary oversight, typically at higher doses and often with therapeutic drug monitoring.

What the label says about safety

Contraindications

• Do not use in dogs with a history of neoplasia (cancer).
• Do not use in dogs with known hypersensitivity to cyclosporine.

Warnings

The label states: "Atopica (cyclosporine) is a systemic immunosuppressant that may increase the susceptibility to infection and the development of neoplasia."

Use restrictions

• Not for use in dogs less than 6 months of age or less than 4 pounds.
• Not for use in breeding dogs, pregnant dogs, or lactating bitches.
• For oral use in dogs only.

Human warnings

The label instructs handlers to wear gloves when administering capsules, not to break or open capsules, and to wash hands after handling. People with known hypersensitivity to cyclosporine should avoid contact entirely.

Side effects

The most common side effects are gastrointestinal and occur most frequently during the first weeks of treatment:

Common (placebo-controlled field study data)

Less common but reported

• Gingival hyperplasia (gum overgrowth) — may require dose reduction or dental intervention; azithromycin-containing toothpaste has been used to manage this.
• Papillomatosis (warts) — dogs infected with papillomavirus may develop large numbers of warts while on cyclosporine.
• Footpad hyperkeratosis (thickened, cracked paw pads).
• Increased shedding or coat changes (hirsutism).
• Elevated serum creatinine — noted in approximately 8% of treated dogs in field studies. This is usually not clinically significant at standard doses, but should prompt a recheck of kidney values.

Serious but rare

• Development of neoplasia, including lymphoma — reported primarily in dogs receiving cyclosporine concurrently with other immunosuppressive drugs.
• Serious infections (bacterial, fungal, protozoal) — including toxoplasmosis, neosporosis, and demodicosis.
• Hepatotoxicity.

If your dog develops persistent vomiting, severe diarrhea, lethargy, swollen gums, unusual lumps, or signs of infection (fever, discharge, coughing), contact your veterinarian.

Dosing and tapering

Starting dose

The label dose is 5 mg/kg once daily (range 3.3–6.7 mg/kg/day). Capsules are available in four strengths:

Administration tips

• Give on an empty stomach — at least 1 hour before or 2 hours after a meal — for best absorption.
• Do not open or break capsules.
• If GI upset occurs, freezing the capsules before administration may reduce vomiting in some dogs. Alternatively, your veterinarian may recommend temporarily giving the capsule with a small amount of food.

Tapering protocol

Once daily dosing continues until satisfactory improvement — typically 4 to 8 weeks. After that, your veterinarian will guide a taper:

1. Daily dosing for the first 4–8 weeks (loading phase).
2. Every other day — once clinical signs are well controlled, many dogs can transition to every-other-day dosing.
3. Twice weekly or every third day — some dogs maintain control at this frequency.

The goal is to find the lowest effective dosing frequency for each individual dog. Do not adjust the dose or frequency on your own — this should always be done under veterinary guidance.

Drug interactions

Cyclosporine has significant drug interactions because it is metabolized by the cytochrome P450 3A enzyme system in the liver. Drugs that inhibit or induce this system can raise or lower cyclosporine blood levels:

Drugs that increase cyclosporine levels

• Ketoconazole and other -azole antifungals (the label specifically notes this interaction — ketoconazole is sometimes intentionally co-administered at a lower dose to allow cyclosporine dose reduction and cost savings).
• Erythromycin and certain other antibiotics.
• Corticosteroids (prednisone, prednisolone).
• Certain calcium channel blockers.

Drugs that decrease cyclosporine levels

• Phenobarbital and other barbiturates.
• Phenytoin.
• Rifampin.
• St. John's Wort (supplement).

Other interactions

• Cyclosporine can increase blood levels of digoxin (a heart medication).
• Concurrent use with other immunosuppressants increases infection and neoplasia risk.
• Grapefruit and grapefruit juice can alter cyclosporine metabolism.

Always tell your veterinarian about every medication, supplement, and over-the-counter product your dog is receiving before starting Atopica.

MDR1 gene mutation

Dogs with the MDR1 (ABCB1) gene mutation — common in Collies, Shetland Sheepdogs, Australian Shepherds, Old English Sheepdogs, and related breeds — may have increased sensitivity to cyclosporine. If your dog is an affected breed, discuss MDR1 genetic testing with your veterinarian before starting Atopica. A dose adjustment may be needed.

Monitoring

For dogs on long-term cyclosporine therapy, veterinary pharmacology sources and the label recommend:

• Baseline bloodwork before starting: complete blood count, chemistry panel (including kidney and liver values), urinalysis.
• Recheck bloodwork at 2–4 weeks after starting, then every 6 months during long-term use. More frequent monitoring is needed for dogs with pre-existing kidney or liver disease.
• Blood pressure monitoring — cyclosporine can cause vasoconstriction in the kidneys; long-term use warrants periodic blood pressure checks.
• Gingival exams — check for gum overgrowth at each veterinary visit.
• Skin and lymph node exams — monitor for new lumps, enlarged lymph nodes, or skin changes.

Therapeutic drug monitoring (blood level testing) is generally not recommended for atopic dermatitis, because the skin tissue level of cyclosporine — not the blood level — determines efficacy, and there is no practical way to measure skin tissue concentration. Drug level monitoring is reserved for dogs being treated for systemic immune-mediated diseases (IMHA, IBD) at higher doses.

When Atopica may fit well

• Dogs with atopic dermatitis that has not responded to antihistamines, fatty acid supplementation, and topical therapy.
• Dogs that cannot tolerate steroids or where long-term steroid use poses unacceptable risks (diabetes risk, liver disease, Cushingoid changes).
• Dogs that have not responded to or are not candidates for Apoquel or Cytopoint.
• Dogs with concurrent conditions where cyclosporine's broad immunomodulatory effect may address both atopic dermatitis and an extra-label condition (e.g., perianal fistulae, sebaceous adenitis, certain immune-mediated skin diseases) — only under veterinary guidance and often at higher doses.
• Owners who prefer a medication with a 20-year safety track record over newer agents.

When Atopica may not be the right choice

Atopica vs Apoquel vs Cytopoint vs Zenrelia

These four drugs all treat atopic dermatitis in dogs but work through fundamentally different mechanisms. No single drug is universally "better" — the right choice depends on the individual dog.

What to discuss with your veterinarian

• What allergy workup has been done? Atopica treats atopic dermatitis (environmental allergies). If flea allergy, food allergy, or secondary infection has not been ruled out, cyclosporine may not address the right problem.
• Has my dog had recent bloodwork? Baseline kidney, liver, and CBC values are needed before starting.
• What is the taper plan? Ask your veterinarian what the schedule will look like once improvement is seen — daily → every other day → twice weekly is common but individualized.
• What other medications is my dog on? Specifically mention antifungals, antibiotics, steroids, heart medications, supplements, and seizure medications.
• What should I watch for at home? Vomiting and diarrhea are expected early on. Ask when GI signs warrant a call versus when they can be monitored. Ask what signs of infection or gingival changes to look for.
• What if Atopica does not work? Most dogs show some response within 4–6 weeks. If there is no improvement by 8 weeks, discuss whether the dose needs adjustment, a drug interaction is reducing absorption, a secondary infection is flaring, or a different allergy medication should be tried.
• Is my dog an MDR1-affected breed? If yes, testing may be warranted before starting.

Key points

• Atopica is an oral cyclosporine capsule that suppresses T-cell–driven allergic inflammation in dogs with atopic dermatitis.
• It is FDA-approved for dogs ≥6 months old and ≥4 lb. It is contraindicated in dogs with a history of neoplasia.
• The starting dose is 5 mg/kg once daily; after 4–8 weeks, many dogs can taper to every-other-day or less frequent dosing.
• GI side effects (vomiting, diarrhea) are common, especially early. More serious risks include infection and neoplasia due to systemic immunosuppression.
• It has significant drug interactions through the CYP3A system. Always disclose all medications and supplements.
• It is slower to take effect than Apoquel, Cytopoint, or Zenrelia but has the longest post-market safety track record.
• Long-term monitoring with bloodwork every 6 months is recommended.

Sources

• DailyMed — ATOPICA (cyclosporine capsules USP MODIFIED) Full Prescribing Information (NADA 141-218). https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=99642708-0a9f-4ff0-bc08-f2b18691927e
• Elanco — Atopica for Dogs Product Page. https://my.elanco.com/us/atopica-dog
• Merck Veterinary Manual — Immunomodulators for Integumentary Disease in Animals. https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-integumentary-system/immunomodulators-for-integumentary-disease-in-animals
• Veterinary Partner (VIN) — Cyclosporine. https://veterinarypartner.vin.com/doc?id=4952029&pid=19239
• Petrovitch A et al. (2016) — Oral Cyclosporine Treatment in Dogs: A Review of the Literature. Veterinary Medicine: Research and Reports. PMC 4895546. https://pmc.ncbi.nlm.nih.gov/articles/PMC4895546
• Reinhart JM — Therapeutic Drug Monitoring of Cyclosporine in Dogs and Cats. University of Illinois College of Veterinary Medicine. https://vetmed.illinois.edu/2020/04/14/therapeutic-drug-monitoring-of-cyclosporine-in-dogs-and-cats
• Nuttall T et al. (2014) — Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Veterinary Record, 174(Suppl 2):3–12. PMC 3995266. https://pmc.ncbi.nlm.nih.gov/articles/PMC3995266